Foundayo (orforglipron) is approved: what patients should know about the newest GLP-1 pill

GLP-1 receptor agonists (GLP-1 RAs) are a class of drugs that mimic a gut hormone called glucagon-like peptide-1, which plays a role in regulating appetite and blood sugar. Most GLP-1 medications — including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — are peptide-based, which means they're derived from protein chains and typically need to be injected because the digestive system would break them down if swallowed.

Orforglipron is a non-peptide (small molecule) GLP-1 receptor partial agonist. Being small and non-peptide means it survives the digestive process well enough to be absorbed as a tablet. It does not have the stomach-emptying requirements of oral semaglutide, which requires 30 minutes of fasting before and after each dose with a specific amount of water.

The FDA approved Foundayo under its Commissioner's National Priority Voucher (CNPV) pilot program, completing the review 50 days after filing.

If the peptide vs non-peptide distinction is new to you, our explainer on GLP-1s vs peptides covers it in more depth.

The FDA-approved indication for Foundayo is: use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with:

• A BMI of 30 or higher (obesity), or
• A BMI of 27 or higher (overweight) plus at least one weight-related comorbid condition

These are the same eligibility criteria that apply to the injectable GLP-1 medications approved for obesity. Foundayo should not be used in combination with another GLP-1 receptor agonist.

The FDA approval was supported by two randomized, double-blind, placebo-controlled trials in adults meeting the above criteria. In both trials, 72 weeks of treatment with Foundayo, combined with a reduced-calorie diet and increased physical activity, resulted in statistically significant and clinically meaningful body weight reduction compared with placebo. The FDA press announcement confirms both trials met their primary endpoints; full efficacy data is in the complete prescribing information.

Boxed warning: Risk of thyroid C-cell tumors. Foundayo should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.

Other warnings and precautions include: pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia (particularly in patients on insulin or insulin secretagogues), hypersensitivity reactions, diabetic retinopathy in patients with type 2 diabetes, acute gallbladder disease, and risk of pulmonary aspiration during general anesthesia or deep sedation.

Common side effects reported in trials include: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, burping, gastroesophageal reflux disease, gas, and hair loss.

The FDA approved oral semaglutide (Wegovy pill) for weight management in 2025. The key practical difference:

• Oral semaglutide requires being taken on a completely empty stomach, with no more than 4 oz of plain water, with no food, water, or other medications for at least 30 minutes afterward.
• Foundayo has no food or water restrictions.

These are different molecular approaches. They have not been compared head-to-head in a clinical trial. One is not 'better' based on current evidence — the right choice depends on your health profile, other medications, and clinical situation.

For background on the oral semaglutide pill itself, see oral semaglutide is now available in the US.

• Long-term data beyond the trial periods is still emerging. Post-marketing surveillance will continue.
• Insurance coverage and patient access pricing are not yet established across all plans.
• Direct comparison with injectable GLP-1 medications on efficacy has not been established for orforglipron.
• Whether Foundayo's effects on cardiovascular outcomes match those established by the injectables is unknown — a large cardiovascular outcomes trial is expected.

• Does Foundayo's FDA label indication match my situation?
• Given my current medications, are there any interactions or contraindications I should know about?
• How does the approval data compare to what's known about the injectable options I might be considering?
• Is there any reason the thyroid boxed warning is particularly relevant for me?

• Body weight at regular intervals as agreed with your clinician
• Gastrointestinal symptoms — nausea is common early on and often improves
• Any unusual symptoms: abdominal pain (pancreatitis warning), vision changes (retinopathy warning in T2D), signs of allergic reaction
• Your dose escalation schedule — the FDA label describes a starting dose of 0.8 mg, with increases at 30-day intervals based on response and tolerability

Foundayo is a new option for people who qualify for GLP-1 therapy but prefer or require an oral format — particularly those for whom the strict timing requirements of oral semaglutide are a barrier. The approval is based on solid trial data, but it is a new drug and post-market data will continue to accumulate.

Foundayo requires a prescription. Your prescriber is the right person to evaluate whether it fits your health history, your current medications, and your treatment goals.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• FDA press announcement, April 1, 2026. fda.gov
• Foundayo (orforglipron) prescribing information. FDA. accessdata.fda.gov
• Eli Lilly investor press release. investor.lilly.com